Enter your login e-mail to the account
Search
Search parameters
Search results
- STATINS – DO THEY HAVE DOMINANT POSITION IN CARDIOVASCULAR PREVENTION? LIPID LOWERING AND PLEIOTROPIC EFFECTS OF STATINS
doc. MUDr. Daniel Pella, PhD., MUDr. Viola Vargová, PhD., MUDr. Ján Fedačko, MUDr. Richard Raši
(1/2007, clearly ) - IMMUNOMODULATORY EFFECTS OF STATINS
doc. MUDr. František Gazdík, PhD.
(5/2007, clearly ) - Diabetes and heart failure
prof. MUDr. Ján Murín, CSc., doc. MUDr. Jozef Bulas, CSc.
(1/2014, Review articles )
- Patients‘ Expectations From the Treatment of Erectile Dysfunction in 21st. Century
MUDr. Ondřej Trojan
(5/2003, Review articles ) - Sexual dysfunction in Parkinson’s disease
prof. PhDr. Petr Weiss, Ph.D., PhDr. Petra Kotková
(4/2010, Review articles )
- Sexual dysfunction in Parkinson’s disease
prof. PhDr. Petr Weiss, Ph.D., PhDr. Petra Kotková
(3/2010, From the boundary of neurology ) - INHIBITORY CHOLINESTERÁZ V LÉČBĚ ALZHEIMEROVY NEMOCI
MUDr. Martin Brunovský, Ph.D.
(2/2007, Review articles )
- Biological treatment of the small cell lung cancer
MUDr. Peter Kasan
(1/2007, Review articles ) - mTOR inhibitors in the treatment of advanced renal cell carcinoma
MUDr. Radovan Barilla, PhD., MUDr. Zuzana Syčová-Milá
(1/2009, Review articles ) - Chromosomal rearrangements in lung adenocarcinoma – new treatment options
RNDr. Katarína Hlinková
(3/2014, Review articles ) - Future of treatment of multiple myeloma
prof. MUDr. Elena Tóthová, CSc., MUDr. Adriana Kafková, PhD.
(6/2013, Focus ) - Molecular markers of targeted therapy in oncology malignancies
RNDr. Katarína Hlinková
(2/2010, Review articles ) - Gastrointestinal toxicity, hepatotoxicity and nephrotoxicity of targeted treatment
MUDr. Branislav Bystrický, MUDr. Alexandra Szabová
(1/2013, Main topic ) - Treatment of ALK-rearranged non-small cell lung cancer
MUDr. Zuzana Pribulová
(6/2015, Main topic ) - Myelofibrosis – diagnosis, management, new treatment options
MUDr. Anna Vallová
(6/2015, Review articles ) - Publikujeme v zahraničí
(6/2015, Information & comments ) - Immunotherapy and targeted treatment for metastatic, castration-resistant prostate cancer
MUDr. Ján Slopovský, JUDr. MUDr. Patrik Palacka, PhD., MPH, MBA, LL.M.
(4/2022, Main topic ) - Systemic treatment of bladder cancer – neoadjuvant, adjuvant and palliative chemotherapy
MUDr. Branislav Bystrický, MUDr. Filip Kohútek, MUDr. Peter Kohútek, MUDr. Tomáš Sedláček
(3/2016, Review articles ) - Future of treatment of chronic myeloid leukemia (CML)
prof. MUDr. Elena Tóthová, CSc., MUDr. Adriana Kafková, PhD.
(5/2012, Main topic ) - Selected drug interactions in oncology
MUDr. Veronika Ballová, MUDr. Ján Rajec, PhD.
(5/2011, Review articles ) - New mechanism of action in the treatment of renal cell carcinoma: m-TOR – a novel target
MUDr. Hana Študentová, prof. MUDr. Bohuslav Melichar, Ph.D.
(5/2010, Review articles ) - First line treatment of metastatic renal cell cancer in 2014
MUDr. Mária Rečková
(4/2014, Main topic ) - Nové perspektívy v liečbe pokročilého a metastatického HR+ HER2- karcinómu prsníka
MUDr. Miroslava Malejčíková, MUDr. Silvia Jurišová
(2/2018, Review articles ) - Dual inhibition after failure of NSAI as a solution to hormone therapy resistance
MUDr. Bibiána Vertáková Krakovská, PhD.
(1/2015, Review articles ) - Childhood acute lymphoblastic leukemia: from genome to patient
doc. MUDr. Alexandra Kolenová, PhD.
(1/2016, Main topic ) - New possibilities and view for treatment of castration resistent prostate cancer
doc. MUDr. Igor Andrašina, CSc., MUDr. Radovan Barilla, PhD.
(1/2012, Review articles ) - Therapy for chronic myeloid leukemia: Past, present and future
prof. MUDr. Elena Tóthová, CSc.
(1/2012, Topic of the year ) - Mantle cell lymphoma
MUDr. Radoslav Greksák, PhD.
(1/2024, Main topic ) - Ribociclib, inhibitor of cyclin-dependent kinases 4 and 6, in the treatment of HR+/HER2 - advanced breast cancer
MUDr. Mária Rečková
(1/2017, Drugs & drug classes ) - Palbociclib in the treatment of advanced breast cancer
MUDr. Branislav Bystrický
(1/2017, Drugs & drug classes )
- STATÍNY – MAJÚ DOMINANTNÉ MIESTO V KARDIOVASKULÁRNEJ PREVENCII? LIPIDY ZNIŽUJÚCE A PLEIOTROPNÉ ÚČINKY STATÍNOV
doc. MUDr. Daniel Pella, PhD.
(2/2007, clearly )